Intramuscular ziprasidone reduced symptoms and was well tolerated in acute psychosis


QUESTIONS: In patients admitted to hospital with acute psychotic agitation, how efficacious and tolerable is intramuscular (IM) ziprasidone compared with IM haloperidol, both followed by oral treatment?

Design
Randomised (unclear allocation concealment*), unblinded*, controlled trial with 7 days of follow up.

Setting
19 centres in 7 countries.

Patients
132 patients (mean age 34 y, 93% men) recently admitted to hospital with acute psychosis as defined by DSM-III-R. Exclusion criteria included acute psychosis related to substance abuse or of organic origin.

Intervention
90 patients received up to 3 days of IM ziprasidone (initial dose of 10 mg followed by IM doses of 5–20 mg every 4–6 h [maximum daily dose 80 mg] if needed, then 80–200 mg/d orally to day 7) while 42 received IM haloperidol (initial dose of 2.5–10 mg followed by 2.5–10 mg IM every 4–6 h [maximum daily dose 40 mg] if needed, then by 10–80 mg/d orally).

Main outcome measures
Scores on the Brief Psychiatric Rating Scale (BPRS) total, BPRS agitation items, and Clinical Global Impressions severity (CGI-S) scale, and adverse effects.

Main results
Between 93% and 100% of patients were included in the analyses. Mean reductions from baseline in BPRS total, BPRS agitation items, and CGI-S scores were greater with IM ziprasidone than with IM haloperidol (table 1). Further reductions from baseline were seen after the transition from IM to oral treatment but a statistical difference between treatment groups was seen only for the change in CGI-S scores (table 1). Fewer patients reported adverse effects with IM ziprasidone than with IM haloperidol (table 2).

Conclusions
In patients with acute psychosis, intramuscular (IM) ziprasidone reduced symptoms and was well tolerated compared with IM haloperidol.

Intramuscular ziprasidone v IM haloperidol in acute psychosis‡

<table>
<thead>
<tr>
<th>Outcome up to day 3</th>
<th>IM ziprasidone</th>
<th>IM haloperidol</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPRS total</td>
<td>−6.24 (8.30)</td>
<td>−3.18 (6.55)</td>
<td>0.02</td>
</tr>
<tr>
<td>BPRS agitation items</td>
<td>−1.93 (3.41)</td>
<td>−0.80 (2.81)</td>
<td>0.02</td>
</tr>
<tr>
<td>CGI-S</td>
<td>−0.49 (0.68)</td>
<td>−0.15 (0.53)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Main outcome measures
Scores on the Brief Psychiatric Rating Scale (BPRS) total, BPRS agitation items, and Clinical Global Impressions severity (CGI-S) scale, and adverse effects.

Main results
Between 93% and 100% of patients were included in the analyses. Mean reductions from baseline in BPRS total, BPRS agitation items, and CGI-S scores were greater with IM ziprasidone than with IM haloperidol (table 1). Further reductions from baseline were seen after the transition from IM to oral treatment but a statistical difference between treatment groups was seen only for the change in CGI-S scores (table 1). Fewer patients reported adverse effects with IM ziprasidone than with IM haloperidol (table 2).

Conclusions
In patients with acute psychosis, intramuscular (IM) ziprasidone reduced symptoms and was well tolerated compared with IM haloperidol.

*See glossary.

COMMENTARY
In treating acute psychosis, clinicians are sometimes required to use antipsychotics in an IM formulation. Haloperidol has come to represent the ‘gold standard’ for conventional antipsychotics in this respect. Its extrapyramidal side effects in particular, however, have posed problems in the clinical setting, and clinicians have been anxious to have a short acting IM formulation of an ‘atypical’ antipsychotic.

This study by Brook et al provides a comparison of IM ziprasidone and haloperidol in acutely psychotic patients where IM treatment was seen as warranted, at least in the initial stages. The authors point out that the design “mimicked real life clinical practice”, that is, acute treatment over a 1 week interval, during which the IM medications were replaced by their oral counterparts within 3 days. While concomitant medications were allowed, including a benzodiazepine, details are not provided as to how they were used and to what extent.

Clinicians must distinguish between behavioural control and antipsychotic efficacy. The data here support ziprasidone’s superiority on measures of global outcome, as well as a score for agitation. It would be interesting to have a comparison focused on psychotic symptoms specifically.

The finding that problems in the QTc interval were not encountered will be reassuring to clinicians, given the reported link between ziprasidone and QTc prolongation and the recent publicity this topic has received.

The conclusions of this study stand, but must be viewed in the context of several caveats. In the treatment of acute psychosis, administering haloperidol in combination with a benzodiazepine from the outset of treatment has become routine; the present study did not exclude benzodiazepine use but it did not mirror actual clinical practice in this respect. The authors rightfully point out that the haloperidol doses are in line with what can be seen in clinical practice, but this is not to say that these doses are necessarily correct. Indeed, more recent evidence would suggest that the doses used were too high.1 This touches upon the final point, which relates to outcome measures. IM ziprasidone was found in this study to be superior to haloperidol in terms of tolerability as well as measures of agitation and global outcome. Each of these, though, could be negatively influenced by excessively high doses of haloperidol.

Gary Remington, MD, PhD, FRCP(C)
Centre for Addiction and Mental Health
Toronto, Ontario, Canada


10.1136/ebmh.4.3.74

74 Volume 4 August 2001 EBMH www.ebmentalhealth.com Therapeutics